Goldman Sachs Maintains Neutral on IDEAYA Biosciences, Raises Price Target to $35

Benzinga Newsdesk www.benzinga.com Positive 50.1%

Neg 0% Neu 0% Pos 50.1%

Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Neutral and raises the price target from $31 to $35.